RSI Overbought Stocks
GUD.CA is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
KNIGHT THERAPEUTICS INC (GUD.CA) Stock Price & Overview
TSX:GUD • CA4990531069
Current stock price
7.45 CAD
+0.01 (+0.13%)
Last:
The current stock price of GUD.CA is 7.45 CAD. Today GUD.CA is up by 0.13%. In the past month the price increased by 19.77%. In the past year, price increased by 27.13%.
GUD.CA Key Statistics
52-Week Range5.43 - 7.5
Current GUD.CA stock price positioned within its 52-week range.
1-Month Range6.04 - 7.5
Current GUD.CA stock price positioned within its 1-month range.
- Market Cap
- 730.324M
- P/E
- N/A
- Fwd P/E
- 155.29
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
GUD.CA Stock Performance
Today
+0.13%
1 Week
+5.23%
1 Month
+19.77%
3 Months
+26.06%
Longer-term
6 Months +27.35%
1 Year +27.13%
2 Years +29.12%
3 Years +65.56%
5 Years +37.96%
10 Years -7.91%
GUD.CA Stock Chart
GUD.CA Stock Screens
GUD.CA currently appears in the following ChartMill screener lists.
GUD.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GUD.CA. When comparing the yearly performance of all stocks, GUD.CA turns out to be only a medium performer in the overall market: it outperformed 69.6% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
GUD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GUD.CA. GUD.CA has an excellent financial health rating, but there are some minor concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GUD.CA Earnings
On March 19, 2026 GUD.CA reported an EPS of 0.09 and a revenue of 133.11M. The company beat EPS expectations (1288.12% surprise) and beat revenue expectations (12.31% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS ReportedCA$0.09
Revenue Reported133.106M
EPS Surprise 1,288.12%
Revenue Surprise 12.31%
GUD.CA Forecast & Estimates
10 analysts have analysed GUD.CA and the average price target is 8.36 CAD. This implies a price increase of 12.15% is expected in the next year compared to the current price of 7.45.
For the next year, analysts expect an EPS growth of 219.94% and a revenue growth 13.69% for GUD.CA
Analysts
Analysts78
Price Target8.36 (12.21%)
EPS Next Y219.94%
Revenue Next Year13.69%
GUD.CA Groups
Sector & Classification
GUD.CA Financial Highlights
Over the last trailing twelve months GUD.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -180% compared to the year before.
Income Statements
Revenue(TTM)450.09M
Net Income(TTM)-5.37M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.51% | ||
| ROE | -0.7% | ||
| Debt/Equity | 0.08 |
Chartmill High Growth Momentum
EPS Q2Q%-18.18%
Sales Q2Q%37.42%
EPS 1Y (TTM)-180%
Revenue 1Y (TTM)21.22%
GUD.CA Ownership
Ownership
Inst Owners16.05%
Shares98.03M
Float52.53M
Ins Owners1.89%
Short Float %N/A
Short RatioN/A
GUD.CA Competitors/Peers
The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.23 | 2.772B | ||
| CRON | CRONOS GROUP INC | 39.18 | 1.338B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.066B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 5.17 | 904.914M | ||
| DHT-U | DRI HEALTHCARE TRUST | 3.83 | 671.122M | ||
| WEED | CANOPY GROWTH CORP | N/A | 565.768M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 22.49 | 475.264M | ||
| TSND | TERRASCEND CORP | N/A | 349.699M | ||
| HITI | HIGH TIDE INC | 10.35 | 283.038M | ||
| ACB | AURORA CANNABIS INC | 59.28 | 271.641M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.16 | 261.773M | ||
| CRDL | CARDIOL THERAPEUTICS INC-A | N/A | 221.245M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About GUD.CA
Company Profile
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.
Company Info
IPO: 2014-02-28
KNIGHT THERAPEUTICS INC
3400 De Maisonneuve Blvd W
MONTREAL QUEBEC H3Z 3B8 CA
CEO: Jonathan Ross Goodman
Employees: 745
Phone: 15144844483
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you describe the business of KNIGHT THERAPEUTICS INC?
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.
What is the current price of GUD stock?
The current stock price of GUD.CA is 7.45 CAD. The price increased by 0.13% in the last trading session.
Does KNIGHT THERAPEUTICS INC pay dividends?
GUD.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of GUD stock?
GUD.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists GUD stock?
GUD.CA stock is listed on the Toronto Stock Exchange exchange.
Is KNIGHT THERAPEUTICS INC (GUD.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GUD.CA.
Who owns KNIGHT THERAPEUTICS INC?
You can find the ownership structure of KNIGHT THERAPEUTICS INC (GUD.CA) on the Ownership tab.